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Abstract
Objective: In  patients  with  multiple  myeloma,  ben-
damustine monotherapy is effective as 1st and 2nd line
therapy.  However,  data  for  patients  with  advanced
multiple myeloma is rare. 
Methods: In this retrospective analysis we have identi-
fied 39 patients with relapsed or refractory multiple
myeloma by means of case research, who have been
treated at our institution with bendamustine as salvage
therapy.  after  in  median  2  lines  of  prior  therapy
(range:1-5) patients received in median 3 (range: 1-10)
cycles of bendamustine. Bendamustine dosage was 80-
150 mg on day 1+2 of a monthly cycle. Bendamustine
was administered as monotherapy in 39% of patients,
whereas 61% received concomitant steroids.
Results: toxicity was mild to moderate. Response rates
were as follows: 3% vgPR, 33% PR, 18% MR, 26%
sd and 20% Pd. the median event-free and overall
survival were 7 and 17 months, respectively. 
Conclusions: In conclusion, in patients with advanced
multiple myeloma bendamustine is effective and asso-
ciated with mild toxicity. therefore, the role of ben-
damustine in patients with multiple myeloma should
be investigated in further clinical trials.
Key words: Bendamustine, multiple myeloma, relapsed/
refractory
1. IntRoductIon
High-dose chemotherapy followed by autologous pe-
ripheral blood stem cell transplantation (PBsct) has
improved response rates and survival in patients with
multiple myeloma [1, 2]. despite further dose escala-
tion, almost all patients ultimately suffer from disease
progression  [3,  4].  therefore,  there  is  a  continuous
need to broaden the spectrum of salvage therapies for
those patients [5]. In addition to novel agents such as
thalidomide [6], lenalidomide [7] and bortezomib [8],
conventional cytotoxic chemotherapy remains a treat-
ment option in this situation. In this respect one may
consider bendamustine, which is a bifunctional alky-
lating agent. It is characterised by a unique profile of
cytotoxicity and there is only partial cross-resistance
with other alkylating agents or anthracyclines [9, 10;
12].  Bendamustine  is  used  for  the  treatment  of 
non-Hodgkin-lymphoma  and  chronic  lymphatic  leu-
caemia, but also for therapy of lung and breast cancer
[10-19]. 
In myeloma cells, bendamustine induces a G2 cell
cycle arrest and p53-mediated apoptosis [20]. In pa-
tients  with  multiple  myeloma,  efficacy  has  been  re-
ported as a single-agent as well as in combination with
other agents, while the toxicity observed was mild and
mainly haematological [21-26]. Poenisch et al. random-
ized patients with newly diagnosed multiple myeloma
to either a bendamustine/prednisone regimen or stan-
dard melphalan/prednisone. the overall response rate
(minimal  response  (MR)  +  partial  response  (PR)  +
complete response (cR)) was the same with both regi-
men, but the treatment with bendamustine led to an
increased cR rate (32% vs. 13%, p = 0.007). the dura-
tion of remission in patients with cR or PR was also
significantly  longer  (18  months  vs.  12  months,  p  <
0.02), while the median overall survival (os) was not
significantly  different  (32  vs.  33  months).  still,  the
quality of life was better in the group of patients who
received bendamustine [23].
In patients with first relapse after high dose therapy
and autologous PBsct, Knop et al. observed an over-
all response rate of 55% with bendamustine as salvage
therapy.  In  this  study  a  median  event-free  survival
(Efs) of six months was observed [24]. In combina-
tion with prednisolone and thalidomide bendamustine
resulted in response rates of 80% in patients with re-
lapsed and refractory multiple myeloma [25]. In anoth-
er trial patients not responding to a bortezomib/dex-
amethasone regimen received a triple therapy consist-
ing of bortezomib, dexamethasone and bendamustine,
which resulted in a 57% response rate [26], another
study reports an overall response rate of 88% in this
combination [27].
In conclusion, there is evidence that bendamustine
is effective in different stages of multiple myeloma.
However,  there  is  no  data  for  bendamustine
monotherapy  in  patients  with  advanced  disease.
therefore, we report on 39 patients in this situation. 
2. MatERIal, MEtHods and statIstIcs
2.1 PatIEnts
we conducted a retrospective analysis of patients with
advanced  multiple  myeloma  who  have  been  treated
with  bendamustine  at  our  institution  between  april
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macy  records  we  identified  patients  with  multiple
myeloma who have been treated with bendamustine.
as concomitent treatment, only steroids and radiation
therapy were allowed. Exclusion criteria for this retro-
spective analysis were treatment with other combina-
tion  partners,  dosage  of  less  than  80  mg/m2,  prior
bendamustine treatment, first-line treatment or miss-
ing data concerning remission rate and event-free sur-
vival. clinical data of patients included in the analysis
was  obtained  by  the  means  of  case  research.  Ben-
damustine  was  approved  for  treatment  of  myeloma
patients in Germany and all patients gave written in-
formed consent for treatment with bendamustine.
2.2 tREatMEnt scHEdulE
Bendamustine  hydrochloride  was  administered  intra-
venously at a dose of 80-150 mg/m2 in 500 ml nacl
0.9% over 30 minutes on day 1 + 2. the dose was as-
sessed by the physician according to the health state
and  the  comorbidity  of  the  patient.  corticosteroids
were  chosen  as  concomitant  treatment  according  to
the treating physicians decision, without any detectable
pattern for decision making. the steroids used were
either prednisolone 100 mg on day 1-5 or dexametha-
sone 40 mg on day 1+2. cycles were repeated in me-
dian after 28 days (range: 14-90 days). Growth factors
and antibiotic prophylaxis were not used. treatment
was  continued  until  either  induction  of  remission 
(≥ PR) or disease progression occurred. 
2.3 statIstIcal MEtHods
treatment response and duration of remission were
assessed  according  to  the  EBMt  criteria  [28].  the
Efs was calculated for all patients, who achieved at
least a minimal response, from the date of first ben-
damustine treatment to the time of disease progres-
sion,  relapse  or  death.  os  was  calculated  from  the
date of starting bendamustine treatment to the date
of death. Kaplan-Meier curves for Efs and os were
plotted and compared with the use of the log-rank
test. adverse events were assessed as documented in
patients records according to ctc aE criteria version
3.0. the two-sided fisher exact test was used to com-
pare  the  response  rates  or  the  number  of  adverse
events.  Prognostic  factors  were  determined  by 
univariate analysis and the use of the log rank test.
the following parameters were included in the uni-
variate analysis: age (</> 65 years), refractory (not
achieving at least stable disease by last treatment line)
or relapsed (progressive disease after achieving at least 
stable disease by last treatment line) disease, mono  -
therapy  versus  concomitant  steroids,  bendamustine
dose (80-100 or 120-150 mg/m2), prior thalidomide
or  prior  high-dose  therapy  and  autologous  stem 
cell transplantation (yes or no), extramedullary mani-
festation (yes or no), cytogenetic abnormalities (kary-
otype  normal  versus  abnormal),  osteolytic  lesions 
(yes or no), Iss stage (I vs. II/III), ldH (</> 200
u/l),  cRP  (</>  0.6  mg/dl),  haemoglobine  level
(</> 10 g/dl), platelet count (</> 200.000/ﾵl), hy-
percalciaemia (</> 2.6 mmol/l), elevated creatinine
(</> 1.2 mg/dl). ssPs V14.1 was used for statistical
analysis. 
3. REsults
3.1 PatIEnt cHaRactERIstIcs
using pharmacy records we could identify 75 patients
with  multiple  myeloma  who  received  bendamustine
treatment in our institution. of all, 39 patients en-
tered the retrospective analysis. Reasons for exclusion
from the analysis were insufficient data (n = 19), com-
bination partners other than steroids (n = 10), first-
line treatment (n = 5), total bendamustine dosage of
less than 80 mg/m2 (n = 2). the patients in our study
had an advanced stage of disease as reflected by a me-
dian of two lines of prior treatment regimen (range:
1-5). this includes high-dose therapy and autologous
PBsct in 64% of the patients and a second high-
dose  therapy  as  salvage  treatment  in  23%.  Prior
thalidomide treatment had been administed in 59% of
the patients. of all patients, 54% were refractory to
the last salvage therapy, whereas 46% suffered from
progressive disease after a remission or stable disease
had been achieved by the antecedent therapy. about
one third of patients presented with extramedullary
manifestations  (28%).  Patient  characteristics  before
the  begin  of  bendamustine  treatment  are  shown  in
table 1.
3.2 tREatMEnt PRofIlE
Patients received a median of 3 (range 1-10) cycles of
bendamustine. of all, 25 patients (64%) received ben-
damustine treatment until disease progression. these
patients were treated with in median 4 cycles (1-10). In
13  patients  (33%)  bendamustine  treatment  was
stopped after in median 3 cycles (1-9) during ongoing
remission.
the  median  dose  was  100  mg/m2 (range  80-150
mg/m2) on day 1+2. for our evaluation the patients
were retrospectively allocated to two different groups
according to the administered dose of 80-100 mg/m2
(n = 20) versus 120-150 mg/m2 (n = 19).
dose reduction was necessary in 28% (n = 11) of
the  patients  because  of  haematological  side  effects,
while a discontinuation was not neccessary for any of
the patients. 31% of the patients received bendamus-
tine monotherapy and 69% received bendamustine in
combination with corticosteroids. 
3.3 REsPonsE RatEs
the overall response rate (cR+PR) was 36% (table
2).  no  cR  was  observed.  In  one  case  (3%),  a  very
good PR could be achieved while 13 patients entered
into a PR (33%). a MR was observed in 7 patients
(18%),  whereas  stable  and  progressive  disease  were
noted in 10 (26%) and 8 (20%) patients, respectively.
subgroup analysis showed no significant differences
in outcome in relation to the dose of bendamustine
administered (table 2). within the subgroup of pa-
tients who had received a dose of 80-100 mg/m2, the
rate of PR was 33% compared with 38% in the group
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2. Bölke_Umbruchvorlage  20.01.10  12:39  Seite 15of  patients  who  had  received  120-150  mg/m2 (p  =
0.75).
In the same way, bendamustine monotherapy result-
ed in a PR rate of 25%, which was not statistically dif-
ferent  from  combination  therapy  of  bendamustine
with corticosteroids (40%, p = 0.48, table 2).
there also were no differences in terms of remis-
sion rates for patients older than 65 years or younger
patients. the same was true for patients who had re-
ceived a prior high-dose therapy with PBsct or who
were  treated  with  conventional  chemotherapy  (data
not shown).
3.4 EVEnt-fREE and oVERall suRVIVal
for the entire group of patients, the median Efs was
7 months and the median time of os was 17 months
(fig. 1). the major reason for the relatively short sur-
vival time was disease progression and not toxicity.
univariate analysis did show metaphase cytogenet-
ics as a prognostic parameter for Efs. this was dif-
ferent for os. Patients with Iss stage II or III, refrac-
tory disease, elevated ldH (> 200 u/l), elevated cRP
level (> 0.6 mg/dl), and anaemia (haemoglobine level
< 10 g/dl) had a significantly shorter os time (table
3).
there  were  no  significant  differences  in  outcome
between  the  two  subgroups  receiving  either  ben-
damustine monotherapy or combination therapy with
steroids. the dose of bendamustine also had no influ-
ence on the patients’ outcome. there also were no sta-
tistically  differences  between  patients  older  than  65
EuRoPEan JouRnal of MEdIcal REsEaRcH 16 January 29, 2010
Table 2. Response rates & subgroup analysis.
Subgroups dosage Subgroups therapy mode
80-100 mg/m2 120-150 mg/m2 Monotherapy + Steroids
n = 39 n = 21 n = 18 p n = 12 n = 27 p
PR 14 (1 vgPR) 36% 7 33% 7 38%  0.8 3 25% 11 40%  0.5
MR 7 18% 4 19% 3 17% 1.0 2 17% 5 19% 1.0
SD 10 26% 7 33% 3 17% 0.3 5 42% 5 19% 0.2
PD 8 20% 3 15% 5 28% 0.4 2 17% 6 22% 1.0
vgPR very good partial remission;  PR partial remission; MR Minor remission; sd stable disease; Pd progressive disease
Table 3. univariate analysis.
EFS OS
Iss stage (I vs. II+II) 0.2 0.001
cytogenetics (normal vs. abnormal karyotype) 0.05 0.2
ldH (</> 200 u/l) 0.5 0.02
cRP (</> 0.6 mg/dl) 0.7 0.001
Haemoglobine level (</> 10 g/dl) 0.2 0.04
Platelet count (</> 200.000/ﾵl) 0.6 0.1
chemosensitivity (relapse vs. refractory) 0.4 0.01
Prior thalidomide 0.4 1.0
Prior high-dose therapy 0.5 0.4
Extramedullary manifestation 0.4 0.2
osteolytic lesions 0.5 0.3
Bendamustine dosage </> 120 mg/m2 0.6 0.9
Monotherapy vs. steroid combination therapy 0.7 0.3
Fig. 1. overall survival of 39 patients with refractory or relapsed MM treated with bendamustine and event-free survival of 21 pa-
tients with refractory or relapsed MM responding (MR+PR+cR) to bendamustine treatment.
Overal survival Event-free survival
Median 17 months Median 7 months
2. Bölke_Umbruchvorlage  20.01.10  12:39  Seite 16years  and  younger  patients  or  patients,  which  were
treated with a prior PBsct or not. 
3.5 toxIcIty
In our study, toxicity was mild (table 4) and consisted
mainly of haematological adverse events. In 95% of
the patients, haematological side effects were observed
after administration of one cycle of bendamustine. In
most cases (69%) grade 1 and 2 cytopenia were ob-
served, which did not postpone further treatment. se-
vere  anaemia  requiring  red  blood  cell  transfusions
(grade 3/4) developed in 4 patients (10%), while se-
vere thrombocytopenia (grade 3/4) was observed in
10 (26 %) patients. there were 16 (41%) patients with
grade 3/4 neutropenia and 6 of them (15%) required
iv antibiotic treatment and hospitalisation. one patient
had a paravertebral abscess with spondylodiscitis re-
quiring surgical intervention. this patient had received
concomitant steroids.
non-haematological  toxicity  included  mainly  gas-
trointestinal  complaints.  Grade  1  and  2  nausea  and
vomiting was observed in 8% (n = 3). In two patients
(5%), grade 1/2 diarrhea was developed. other grade
1/2 toxicities consisted of fatigue (n = 2), increase of
creatinine (n = 3), paraesthesia (n = 1) and urticaria af-
ter application of bendamustine (n = 1). as a result,
no grade 3/4 non-haematological toxicities were en-
countered. alopecia was not reported for any of our
patients. 
there was no statistically significant difference with
regard to haematologic toxicity between the different
treatment groups. as far as the dose of bendamustine
is  concerned,  there  was  no  correlation  between  the
dose level of bendamustine and the degree and type of
toxicity.  concentrating  on  differences  between  ben-
damustine monotherapy and concomitant steroid ther-
apy, haematological side effects were similar in both
groups. on the other hand, infections were significant-
ly more frequent in patients receiving corticosteroids
(0% vs. 33%, p = 0.04, table 4).
there were no differences in terms of toxicity for
patients older than 65 years or younger patients. In the
same way patients who had received a prior high-dose
therapy  with  autologous  stem  cell  transplantation
showed the same toxicity as patients who were treated
with conventional chemotherapy.
4. dIscussIon
Bendamustine is a treatment option for patients with
relapsed and refractory multiple myeloma in particular
because of its low toxicity either as single agent or in
combination. Herein, we present retrospective data of
39 patients with advanced multiple myeloma, showing
that bendamustine is an effective agent in this treat-
ment situation. the rate of PR was 36%, which is sim-
ilar  to  other  salvage  therapies.  noteworthy,  in  our
study with a heterogeneous patient population we did
not observe a better therapeutic efficacy when steroids
were added. In contrast the concomitant administra-
tion  of  steroids  was  associated  with  a  significantly
higher rate of infections. 
the major finding of our study is, that bendamus-
tine  is  effective  in  patients  with  advanced  multiple
myeloma,  while  published  data  mainly  focus  on  the
role  of  bendamustine  in  early  stages  of  the  disease
[23, 24]. salvage therapies with single agents generally
results in a cR or PR in one third of patients with
multiple  myeloma.  this  also  holds  true  for  novel
agents  such  as  thalidomide  [6]  or  bortezomib  [8].
thus, the rate of 36% PR, which we observed in pa-
tients with in median 2 lines of prior therapy, includ-
ing 56% of patients not achieving at least sd to their
last line of therapy, meets the expected overall remis-
sion rate for an effective anti-myeloma agent. Howev-
er, only one vgPR and no immunofixation negative cR
could be achieved. this result scales down the expec-
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Table 4. toxicity.
Subgroups therapy mode Subgroups dosage
Toxicity All Monotherapy + Steroids p 80-100 mg/m2 100-120 mg/m2 p
n = 39 n = 12 n = 27 n = 21 n = 18
Anaemia ° I-II 32 (82%) 10 (84%) 22 (81%) 1,0 17 (81%) 15 (83%) 1,0
° III-IV 4 (10%) 1 (8%) 3 (11%) 1,0 3 (14%) 1 (6%) 0,6
° I-IV 36 (92%) 11 (92%) 25 (92%) 1,0 20 (95%) 16 (89%) 0,6
Neutropenia ° I-II 19 (49%) 5 (42%) 14 (52%) 0,7 8 (38%) 11 (61%) 0,2
° III-IV 16 (41%) 6 (50%) 10 (37%) 0,5 11 (52%) 5 (28%) 0,2
° I-IV 35 (90%) 11 (92%) 24 (89%) 1,0 19 (90%) 16 (89%) 1
Thrombopenia ° I-II 18 (46%) 4 (33%) 14 (52%) 0,3 9 (43%) 9 (50%) 0,7
° III-IV 10 (26%) 4 (33%) 6 (22%) 0,7 8 (38%) 2 (11%) 0,7
° I-IV 28 (72%) 8 (66%) 20 (74%) 0,7 17 (81%) 11 (61%) 0,3
Infection ° I-II 3 (8 %) 0 (0%) 3 (11%) 0,5 2 (10%) 1 (6%) 1,0
° III-IV 6 (15%) 0 (0%) 6 (22%) 0,2 3 (14%) 3 (11%) 1,0
° I-IV 9 (23%) 0 (0%) 9 (33%) 0,04 5 (24%) 4 (17%) 1,0
Other Side Effects ° I-II 12 (31%) 3 (25%) 9 (33%) 0,7 10 (48%) 2 (11%) 0,02
° III-IV 1 (3%) 0 (0%) 1 (4%) 1,0 0 (0%) 1 (6%) 0,5
° I-IV 13 (33%) 3 (25%) 10 (37%) 0,7 10 (48%) 3  (17%) 0,05
2. Bölke_Umbruchvorlage  20.01.10  12:39  Seite 17tations, as quality of response, especially the achieve-
ment of cR, is considered not only a key determinant
of long-term outcome for first-line therapy [29, 30],
but  also  for  salvage  therapies  [31-33].  the  median
event-free  survival  was  seven  months  in  our  study,
which is similar to salvage treatment with bortezomib,
which resulted in an Efs of 6 months [8]. In compari-
son, salvage therapies with immunomodulatory drugs
such as thalidomide and lenalidomide were associated
with a longer Efs of 14 and 11 months, respectively.
In summary, despite the heterogeneous patient popu-
lation  and  the  retrospective  nature  of  our  study  we
provide information regarding the potential efficacy of
bendamustine  in  patients  with  advanced  myeloma,
thus expanding the therapeutic options in this treat-
ment  situation.  However,  our  results  suggest,  that
combination partners should be considered for ben-
damustine in order to further improve treatment out-
come [26, 27]. 
Having in mind, the heterogenity of the bendamus-
tine  dosages  used  and  the  subsequent  difficulties  in
analyzing toxicity, another interesting finding of our
study was, that bendamustine was associated with rela-
tive few and mild side effects even in patients with ad-
vanced disease. as no validated questionnaire has been
used [34, 35], it is speculative that the low toxicity is
also associated with a better quality of life, as has been
reported during first-line treatment [23]. However, the
observed side effects in our heavily pre-treated patient
population were nearly identical to the low toxicity re-
ported for bendamustine treatment in previously un-
treated patients [23]. due to this favourable toxicity
profile bendamustine may be considered as promising
partner for combination therapies [25-27]. 
Many  physicians  add  steroids  to  a  bendamustine
treatment,  because  they  expect  a  positive  synergistic
effect. In our study we could not find a better thera-
peutic efficacy of this combination either in regard to
response rates, Efs or os. at the same time patient
characteristics were not significantly different between
patients treated with concomitant steroids or not. In
contrast, the use of steroids resulted in a higher num-
ber of infectious complications, which we did not ob-
serve with bendamustine alone. therefore, having in
mind the above mentioned caveat of our study it may
be possible to omit steroids in case of recurrent infec-
tious  complications  without  compromising  efficacy.
further prospective trials are needed to evaluate the
exact  role  of  bendumustine,  its  optimal  dosage  and
best combination partners.
In  conclusion,  bendamustine  is  effective  and  well
tolerable in patients with progressive multiple myelo-
ma.  therefore,  it  is  worth  to  further  evaluate  this
agent in forthcoming clinical trials.
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